论文部分内容阅读
目的:观察替普瑞酮治疗萎缩性胃炎的临床疗效。方法:205例慢性萎缩性胃炎(chronic atrophicgastritis,CAG)患者随机分为两组,治疗组(101例)连续口服替普瑞酮胶囊,对照组(104例)口服安慰剂,总疗程20周。观察两组治疗前后症状、胃镜检查及胃黏膜组织学检查改变。结果:治疗组临床症状改善有效率87.1%,对照组52.9%,两组比较差异有统计学意义(P<0.05);胃镜下黏膜改变:治疗组总有效率92.1%,对照组60.6%,两组比较差异有统计学意义(P<0.05)。胃黏膜组织学变化比较显示:治疗组总有效率为90.1%,对照组54.8%,两组比较差异有统计学意义(P<0.05)。结论:替普瑞酮是治疗慢性萎缩性胃炎安全有效的药物。
Objective: To observe the clinical efficacy of teprenone in the treatment of atrophic gastritis. Methods: A total of 205 patients with chronic atrophic gastritis (CAG) were randomly divided into two groups. The treatment group (101 patients) received continuous oral teprenone capsules and the control group (104 patients) took oral placebo for a total of 20 weeks. The symptoms of the two groups before and after treatment, gastroscopy and gastric mucosal histological changes were observed. Results: The effective rate of clinical symptom improvement was 87.1% in the treatment group and 52.9% in the control group, with significant difference between the two groups (P <0.05). The mucosal changes in the treatment group were 92.1% in the treatment group and 60.6% in the control group The difference was statistically significant (P <0.05). The histological changes of gastric mucosa showed that the total effective rate was 90.1% in the treatment group and 54.8% in the control group, with significant difference between the two groups (P <0.05). Conclusion: Teprenone is a safe and effective drug for the treatment of chronic atrophic gastritis.